康焰;
KANG Yan;Department of Critical Care Medicine,West China Hospital of Sichuan University;

• 1:四川大学华西医院重症医学科

摘要(Abstract)：

Sepsis和感染性休克是导致重症患者死亡的主要原因之一。随着对Sepsis病理生理机制和临床诊治研究的逐渐深入,"拯救Sepsis运动(Surviving Sepsis Campaign,SSC)"自2004年起每4年对SSC指南更新一次,使临床诊疗逐渐趋于规范。近10余年的数据显示,Sepsis患者的病死率稳定且呈显著下降趋势。2016年更新的SSC指南在抗感染治疗方面遭遇到了美国感染病学会(Infectious Disease Society of America,IDSA)的挑战,其在官方期刊Clin Infect Dis发表公开立场声明,不再支持SSC指南。这一举动给临床医生借鉴和应用2016年版SSC指南带来很大困惑。深入了解两大学会对于SSC指南争议的本质至关重要,只有回归争议本质,理清分歧的基点,才能更好地使用指南,使其真正成为临床诊治Sepsis和感染性休克的重要参考。
Sepsis and septic shock are among the leading causes of death in critically ill patients. Since considerable advances have been made in understanding their pathophysiology and clinical management,the Surviving Sepsis Campaign( SSC) guideline for sepsis and septic shock is updated every four years since 2004,which aims at standardizing the clinical practice. The mortality of sepsis was significantly decreased based on the data from the last decades. The recent update of SSC was released in 2016,but it was argued against by Infectious Disease Society of America( IDSA) regarding antimicrobial therapy. IDSA published a statement on its official journal,Clinical Infectious Diseases,claiming they did not endorse the SSC guideline,which caused some confusion in clinical references and applications. So it is important to understand the essence of the controversy between these two societies. The guidelines of SSC and IDSA can better instruct the clinical practice for sepsis and septic shock only after the core of the contradiction between them is fully understood.

关键词(KeyWords)： Sepsis;休克;感染;治疗
sepsis;shock;infection;treatment

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 康焰;
KANG Yan;Department of Critical Care Medicine,West China Hospital of Sichuan University;

参考文献(References)：

• [1]Rhodes A,Evans LE,Alhazzani,et al.Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock:2016[J].Crit Care Med,2017,45:486-552.
• [2]IDSA Sepsis Task Force.Infectious Diseases Society of America(IDSA)Position Statement:Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines[J].Clin Infect Dis,2018,66:1631-1635.
• [3]Seymour CW,Liu VX,Iwashyna TJ,et al.Assessment of Clinical Criteria for Sepsis:for the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)[J].JAMA,2016,315:762-774.
• [4]Mermel LA,Allon M,Bouza E,et al,Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection:2009 update by the Infectious Diseases Society of America[J].Clin Infect Dis,2009,49:1-45.
• [5]Jogenfors A,Stark L,Svefors J,et al.A recommendation to perform a blood culture before the administration of intravenous antibiotics increased the detection of Staphylococcus aureus bacteremia[J].Eur J Clin Microbiol Infect Dis,2014,33:789-795.
• [6]Cockerill FR 3rd,Wilson JW,Vetter EA,et al.Optimal testing parameters for blood cultures[J].Clin Infect Dis,2004,38:1724-1730.
• [7]Uzzan B,Cohen R,Nicolas P,et al.Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma:a systematic review and meta-analysis[J].Crit Care Med,2006,34:1996-2003.
• [8]Giamarellos-Bourboulis EJ,Grecka P,Poulakou G,et al.Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia[J].Clin Infect Dis,2001,32:1718-1725.
• [9]Petrikkos GL,Christofilopoulou SA,Tentolouris NK,et al.Value of measuring serum procalcitonin,C-reactive protein,and mannan antigens to distinguish fungal from bacterial infections[J].Eur J Clin Microbiol Infect Dis,2005,24:272-275.
• [10]Eugen-Olsen J.su PAR-a future risk marker in bacteremia[J].J Intern Med,2011,270:29-31.
• [11]Nakstad B.The diagnostic utility of procalcitonin,interleukin-6 and interleukin-8,and hyaluronic acid in the Norwegian consensus definition for early-onset neonatal sepsis(EONS)[J].Infect Drug Resist,2018,11:359-368.
• [12]de Jong E,van Oers JA,Beishuizen A,et al.Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients:a randomised,controlled,open-label trial[J].Lancet Infect Dis,2016,16:819-827.
• [13]Jekarl DW,Lee SY,Lee J,et al.Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis[J].Diagn Microbiol Infect Dis,2013,75:342-347.
• [14]Mustafic'S,Brki c'S,Prnjavorac B,et al.Diagnostic and prognostic value of procalcitonin in patients with sepsis[J].Med Glas(Zenica),2018,15:93-100.
• [15]Miglietta F,Faneschi ML,Lobreglio G,et al.Procalcitonin,C-reactive protein and serum lactate dehydrogenase in the diagnosis of bacterial sepsis,SIRS and systemic candidiasis[J].Infez Med,2015,23:230-237.
• [16]Wacker C,Prkno A,Brunkhorst FM.Procalcitonin as a diagnostic marker for sepsis:a systematic review and metaanalysis[J].Lancet Infect Dis,2013,13:426-435.
• [17]Prkno A,Wacker C,Brunkhorst FM,et al.Procalcitoninguided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and metaanalysis[J].Crit Care,2013,17:R291.